Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News TG Therapeutics Inc TGTX

Healthcare Biotechnology
TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates are Ublituximab IV (anti-CD20 mAb), Ublituximab Subcutaneous (anti-CD20 mAb), Azer-cel, TG-1701 (BTK inhibitor), and TG-1801 (anti-CD47/CD19 bispecific mAb... see more

Recent & Breaking News (NDAQ:TGTX)

TG Therapeutics Reports Third Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance

GlobeNewswire 7 days ago

TG Therapeutics to Host Conference Call on Third Quarter 2025 Financial Results and Business Update

GlobeNewswire 10 days ago

TG Therapeutics Completes Enrollment in the Phase 3 ENHANCE Trial Evaluating its New Simplified Dosing Schedule for BRIUMVI

GlobeNewswire 13 days ago

New Data for BRIUMVI® Demonstrate 89.9% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 6 Years of Continuous BRIUMVI Treatment

GlobeNewswire September 24, 2025

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting

GlobeNewswire September 10, 2025

TG Announces Phase 3 Trial for Subcutaneous BRIUMVI Commenced Enrollment

GlobeNewswire September 8, 2025

TG Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

GlobeNewswire September 4, 2025

TG Therapeutics Announces Completion of Existing Share Repurchase Program and Authorization of New $100 Million Program

GlobeNewswire September 3, 2025

TG Therapeutics to Participate in the Cantor Global Healthcare Conference

GlobeNewswire August 28, 2025

TG Therapeutics Reports Second Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance

GlobeNewswire August 4, 2025

TG Therapeutics to Host Conference Call on Second Quarter 2025 Financial Results and Business Update

GlobeNewswire July 30, 2025

TG Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

GlobeNewswire June 6, 2025

TG Therapeutics to Participate in the Jefferies Global Healthcare Conference

GlobeNewswire June 2, 2025

TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting

GlobeNewswire May 30, 2025

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting

GlobeNewswire May 27, 2025

TG Therapeutics Reports First Quarter 2025 Financial Results and Raises BRIUMVI Full Year Revenue Guidance

GlobeNewswire May 5, 2025

TG Therapeutics to Host Conference Call on First Quarter 2025 Financial Results and Business Update

GlobeNewswire April 30, 2025

TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting

GlobeNewswire April 10, 2025

TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting

GlobeNewswire April 8, 2025

TG Therapeutics Announces Two Publications Highlighting BRIUMVI in Medical Journals

GlobeNewswire April 7, 2025